

Application No.: 09/684,628
Attorney Docket No.: 5259-04700.US.01
Amendment dated June 16, 2005
Reply to Office Action of February 18, 2005


Remarks/Arguments

Claims 1-100 and 284-286 are pending. Claims 1, 14, 23, 42, 58, 59, 70, 79, 80, and 91 have been amended. Claims 13, 33-35, 57, 68, 79, 99-107, and 283 have been cancelled. In the office action dated April 1, 2004, the examiner stated that claims 3, 6-14, 26, 33-36, 38-41, 47, 54-56, 58, 59, 68, 78-80, 85, 87, and 100 would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims. Applicants have amended independent claims 1, 23, 42, 70, and 91 to include the limitations previously recited in claims 13, 33, 57, 78, and 100 respectively. Further, Applicants added claims 284, 285, and 286 to include the limitations previously recited in claims 34, 35, and 68 respectively, including all the limitations of the base claim and any intervening claims. Applicants submit that all claims are now in condition for allowance. Favorable consideration is respectfully requested.

The Commissioner is hereby authorized to charge any additional filing fees required under 37 CFR § 1.16, as well as any patent application processing fees under 37 CFR § 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this page is enclosed.

Respectfully submitted,
McBride, et al.

ABBOTT LABORATORIES
Customer No.: 23492
Telephone: (847) 938-7576
Facsimile: (847) 938-2623


Beth A. Vrioni
Registration No. 39,869
Attorney for Applicants


Remarks/Arguments

Claims 1-100 and 284-286 are pending. Claims 1, 14, 23, 42, 58, 59, 70, 79, 80, and 91 have been amended. Claims 13, 33-35, 57, 68, 79, 99-107, and 283 have been cancelled. In the office action dated April 1, 2004, the examiner stated that claims 3, 6-14, 26, 33-36, 38-41, 47, 54-56, 58, 59, 68, 78-80, 85, 87, and 100 would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims. Applicants have amended independent claims 1, 23, 42, 70, and 91 to include the limitations previously recited in claims 13, 33, 57, 78, and 100 respectively. Further, Applicants added claims 284, 285, and 286 to include the limitations previously recited in claims 34, 35, and 68 respectively, including all the limitations of the base claim and any intervening claims. Applicants submit that all claims are now in condition for allowance. Favorable consideration is respectfully requested.

The Commissioner is hereby authorized to charge any additional filing fees required under 37 CFR § 1.16, as well as any patent application processing fees under 37 CFR § 1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this page is enclosed.

Respectfully submitted,
McBride, et al.

ABBOTT LABORATORIES
Customer No.: 23492
Telephone: (847) 938-7576
Facsimile: (847) 938-2623


Beth A. Vriou
Registration No. 39,869
Attorney for Applicants